While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Patalganga plant received zero observation from USFDA earlier
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
